View Older Stories View More Recent Stories
-
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
-
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
-
Theralase raises $1.3M in private placement for cancer study
-
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
-
Theralase launches $2 million private placement, ends brokered financing
-
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
-
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
-
Theralase(R) Investor Conference Call Reminder
-
Theralase(R) Releases 3Q2025 Financial Statements
-
Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug
-
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
-
Theralase(R) Extends Warrants
-
Theralase(R) Releases 2Q2025 Financial Statements
-
Theralase(R) Closes Non-Brokered Private Placement
-
Theralase(R) Extends Warrants
-
Theralase(R) Closes Non-Brokered Private Placement
-
Theralase Completes Annual General and Special Meeting
-
Theralase Annual General Meeting
-
Theralase(R) 1Q2025 Financial Statements
-
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
-
Theralase to Present Groundbreaking Research at ASTRO 2025
-
Theralase Provides Corporate Update
-
Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association
-
Theralase Discovers New Mechanism of Action of Lead Drug
-
Theralase(R) Closes Non-Brokered Private Placement
-
Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments
-
Ruvidar Demonstrates 7 Year Complete Response
-
Ruvidar Effective in the Treatment of Herpes
-
Theralase(R) Releases 2024 Annual Financial Statements
-
Theralase(R) Closes Non-Brokered Private Placement
-
Theralase(R) Therapy Improves Motor and Non-Motor Function in Parkinson's Patients
-
Theralase(R) Demonstrates Efficacy of Rutherrin(R) in Destruction of Non-Hodgkin's Lymphoma
-
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
-
Theralase(R) Demonstrates Effective Treatment of Herpes
-
Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses
-
Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
-
Theralase(R) Launches Three New Clinical Study Sites in USA
-
Theralase(R) Launches New Clinical Study Site in Canada
-
Theralase(R) Release’s 3Q2024 Financial Statements
-
Theralase(R) Closes Non-Brokered Private Placement
-
Theralase(R) Extends Warrants
-
Theralase(R) Provides Update on Bladder Cancer Clinical Study
-
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
-
Theralase(R) Extends Warrants
-
Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus
-
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
-
Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug
-
Theralase(R) Release’s 2Q2024 Financial Statements
-
Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement
-
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

